The company's financial stability is under pressure as the equity base has declined from $689.3 million in 2024Q1 to $181.4 million in 2026Q1, while the current ratio has tightened to 1.04.
| Total Current Assets | 1.32B | 1.1B | 1.46B | 1.48B | 1.45B | 1.37B | 294.2M | 245.53M |
| Cash & Short-Term Investments | 231.41M | 285.14M | 405.6M | 495.1M | 877.2M | 1.05B | 106.8M | 123.63M |
| Cash Only | 139.99M | 173.71M | 193.86M | 114.33M | 465.3M | 1.05B | 106.8M | 123.63M |
| Short-Term Investments | 91.42M | 111.43M | 211.74M | 380.77M | 411.9M | 0 | 0 | 0 |
| Accounts Receivable | 899.75M | 673.79M | 1.02B | 942.46M | 492.36M | 293.41M | 144.56M | 93.25M |
| Days Sales Outstanding | 55.94 | 41.45 | 61.25 | 79.7 | 75.25 | 70.39 | 43.31 | 42.85 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 190.02M | 137.76M | 35.14M | 42.51M | 81.71M | 18.97M | 33.21M | 24.33M |
| Total Non-Current Assets | 183.76M | 174.59M | 276.21M | 260.79M | 246.19M | 219.06M | 152.16M | 157.27M |
| Property, Plant & Equipment | 24.89M | 25.42M | 36.95M | 40.99M | 31.95M | 20.9M | 16.04M | 18.84M |
| Fixed Asset Turnover | 199.62x | 233.41x | 164.01x | 105.31x | 74.74x | 72.80x | 75.95x | 42.18x |
| Goodwill | 0 | 0 | 24.13M | 24.13M | 2.51M | 0 | 41.54M | 41.54M |
| Intangible Assets | 62.45M | 65.72M | 72.77M | 63.77M | 18.45M | 96.94M | 60.47M | 71.15M |
| Long-Term Investments | 228.16M | 59.79M | 61.76M | 44.75M | 17.35M | 6.69M | 8.5M | 0 |
| Other Non-Current Assets | 96.43M | 23.66M | 80.6M | 87.15M | 175.93M | 94.53M | 25.61M | 25.74M |
| Total Assets | 1.5B | 1.27B | 1.73B | 1.74B | 1.7B | 1.59B | 446.36M | 402.79M |
| Asset Turnover | 3.83x | 4.67x | 3.50x | 2.48x | 1.41x | 0.96x | 2.73x | 1.97x |
| Asset Growth % | -93.32% | -26.68% | -0.4% | 2.56% | 7.01% | 255.37% | 10.82% | - |
| Total Current Liabilities | 1.27B | 1.08B | 1.15B | 977.16M | 535.09M | 356.96M | 266.83M | 199.61M |
| Accounts Payable | 0 | 1.06B | 1.15B | 968.06M | 478.23M | 348.65M | 260.11M | 188.26M |
| Days Payables Outstanding | 47.76 | 63.04 | 69.29 | 83.2 | 76.66 | 87.42 | 84.45 | 89.72 |
| Short-Term Debt | 14.75M | 19.24M | 2.46M | 9.1M | 5M | 8.31M | 3.04M | 3.04M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.26B | 0 | 0 | 0 | 51.87M | 0 | 3.68M | 8.31M |
| Current Ratio | 1.04x | 1.02x | 1.27x | 1.51x | 2.71x | 3.83x | 1.10x | 1.23x |
| Quick Ratio | 1.04x | 1.02x | 1.27x | 1.51x | 2.71x | 3.83x | 1.10x | 1.23x |
| Cash Conversion Cycle | 8.17 | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 51.18M | 68.07M | 111.02M | 102.69M | 121.77M | 137.7M | 464.26M | 435.21M |
| Long-Term Debt | 15.28M | 15.75M | 34.9M | 32.31M | 38.48M | 43.4M | 64.67M | 67.14M |
| Capital Lease Obligations | 10.41M | 1.83M | 6.6M | 10.9M | 9.09M | 7.9M | 5.51M | 7.74M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 10.01M | 12.82M |
| Other Non-Current Liabilities | 35.9M | 50.49M | 69.52M | 59.48M | 74.19M | 86.39M | 384.07M | 347.51M |
| Total Liabilities | 1.32B | 1.14B | 1.26B | 1.08B | 656.86M | 494.66M | 731.09M | 634.82M |
| Total Debt | 30.02M | 36.81M | 43.96M | 52.31M | 52.57M | 59.61M | 73.21M | 77.92M |
| Net Debt | -109.96M | -136.9M | -149.9M | -62.02M | -412.73M | -995.21M | -33.58M | -45.71M |
| Debt / Equity | 0.17x | 0.29x | 0.09x | 0.08x | 0.05x | 0.05x | - | - |
| Debt / EBITDA | -0.08x | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.30x | - | - | - | - | - | - | - |
| Interest Coverage | -119.84x | -59.85x | -39.28x | -28.21x | -19.22x | -61.31x | -6.66x | -11.65x |
| Total Equity | 181.43M | 126.73M | 470.95M | 661.02M | 1.04B | 1.09B | -284.73M | -232.03M |
| Equity Growth % | -223.07% | -73.09% | -28.75% | -36.48% | -4.67% | 483.38% | -22.71% | - |
| Book Value per Share | 10.89 | 7.65 | 28.65 | 40.41 | 63.74 | 73.18 | -18.50 | -15.11 |
| Total Shareholders' Equity | 181.43M | 126.73M | 470.95M | 661.84M | 1.04B | 1.09B | -284.73M | -232.03M |
| Common Stock | 166K | 4.15M | 4.12M | 4.06M | 4.12M | 4M | 2.49M | 2.47M |
| Retained Earnings | -1.93B | -1.98B | -1.59B | -1.33B | -1.06B | -957.68M | -551.19M | -491.14M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 479K | 916K | -88K | -2.3M | -5.56M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | -818K | -611K | -300K | 0 | 0 |
Accumulated deficit and margin compression
As reported in recent financial filings, Agilon Health's equity base has contracted significantly from $689.3 million in 2024Q1 to $181.4 million by 2026Q1, reflecting the persistent impact of accumulated losses that continue to weigh on the company's long-term financial stability and overall balance sheet trajectory.
The consistent decline in shareholders' equity suggests that the company's business model has yet to reach a point of self-sustaining profitability. Investors should monitor whether this trend of capital erosion necessitates future dilutive financing to maintain operational liquidity.
Based on the company's balance sheet data, the accumulated deficit has deepened to $1.9 billion as of 2026Q1, a clear indicator that historical operating losses are systematically consuming the capital base and limiting the company's ability to build a robust equity cushion for future growth.
The persistent negative retained earnings highlight the difficulty the company faces in converting its physician-enablement platform into a profitable enterprise. This structural deficit suggests that the current equity position is fragile and highly sensitive to any further deterioration in medical margin performance.
According to quarterly balance sheet disclosures, the current ratio has compressed from 1.51 in 2023Q4 to 1.04 in 2026Q1, indicating that the company's margin of safety against short-term obligations is narrowing as cash reserves fluctuate in response to medical claims and operational cash requirements.
A current ratio hovering near parity suggests limited flexibility to absorb unexpected spikes in medical utilization or regulatory adjustments. This liquidity profile warrants close observation, as the company lacks a significant buffer to manage potential working capital mismatches.
As indicated by the provided financial statements, the company's asset base is heavily reliant on intangible assets and goodwill, which totaled $62.4 million in 2026Q1, potentially masking the underlying volatility of the business model and the risk of future impairment if physician partnerships underperform expectations.
The reliance on intangible assets suggests that the company's valuation is tied to the perceived value of its physician contracts rather than tangible, liquid assets. If these partnerships fail to deliver the anticipated medical savings, the carrying value of these assets may face downward pressure.
Quick answers to the most common questions about buying AGL stock.
As of 2025, Agilon Health, Inc. (AGL) had total assets of $1.27B including $1.10B in current assets.
Agilon Health, Inc. (AGL) carries total debt of $36.8M, offset by $285.1M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Agilon Health, Inc. (AGL) has total shareholders' equity (book value) of $126.7M ($7.65 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Agilon Health, Inc. (AGL) reported a current ratio of 1.02x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.